Research programme: anti-cancer radiopharmaceutical therapeutics - Radiopharm Ventures
Latest Information Update: 06 Oct 2022
At a glance
- Originator Radiopharm Ventures
- Class Antibodies; Antineoplastics; Radioisotopes; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 13 Sep 2022 Radiopharm Theranostics has formed joint venture with The University of Texas MD Anderson Cancer Center
- 13 Sep 2022 Radiopharm Ventures in-licenses patent and technology for tumour-specific antigen discovery and molecular imaging from University of Texas MD Anderson Cancer Center
- 13 Sep 2022 Preclinical trials in Cancer in Australia (Parenteral) before September 2022